HRP20151308T1 - Antibakterijski derivati kinolina - Google Patents

Antibakterijski derivati kinolina Download PDF

Info

Publication number
HRP20151308T1
HRP20151308T1 HRP20151308TT HRP20151308T HRP20151308T1 HR P20151308 T1 HRP20151308 T1 HR P20151308T1 HR P20151308T T HRP20151308T T HR P20151308TT HR P20151308 T HRP20151308 T HR P20151308T HR P20151308 T1 HRP20151308 T1 HR P20151308T1
Authority
HR
Croatia
Prior art keywords
methyl
phenyl
quinolin
benzyl
alkyl
Prior art date
Application number
HRP20151308TT
Other languages
English (en)
Inventor
J.E.G. Guillemont
D.F.A. Lançois
E.T.J. Pasquier
K.J.L.M. Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20151308T1 publication Critical patent/HRP20151308T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Claims (11)

1. Spoj prema općoj Formuli (Ia) ili Formuli (Ib):  [image] [image] njegova farmaceutski prihvatljiva kisela ili bazična adicijska sol, njegov kvarterni amin, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksidni oblik, naznačen time da: p je cijeli broj jednak nula, 1, 2, 3 ili 4; q je cijeli broj jednak 1, 2 ili 3; Z je radikal odabran od formula: [image] R1 je cijano, halo, alkil, haloalkil, hidroksi, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, arilalkil, di(aril)alkil, aril ili Het; R2 je vodik, alkiloksi, aril, ariloksi, hidroksi, merkapto, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino, pirolidino ili radikal s formulom  [image] pri čemu Y je CH2, O, S, NH ili N-alkil ; R3 je alkil, arilalkil, aril, mono- ili di-alkilaminoalkil, Het ili Het-alkil; R4 i R5 svaki neovisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; Het; ili aril; ili R4 i R5 zajedno s dušikovim atomom na koji su vezani tvore radikal odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, 1,4-diazacikloheptil, 1-aza-4-oksacikloheptil, 1,2,3,4-tetrahidroizokinolin-2-il, 2H-pirolil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, proizvoljno supstituiran s jednim ili više supstituenata, a svaki supstituent je neovisno odabran od alkila, haloalkila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiloksialkila, alkiltioalkila, arila, piridila ili pirimidinila; R6 je aril ili Het; R7 je vodik, halo, alkil, aril ili Het; R8 je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; R9 je vodik ili alkil; R10 je okso; i X je -CH2- ili -CO-; alkil je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma vezanih na ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; pri čemu svaki ugljikov atom može biti proizvoljno supstituiran s cijano, hidroksi, alkiloksi ili okso; aril je homocikal odabran od fenila, naftila, acenaftila ili tetrahidronaftila, koji je svaki proizvoljno supstituiran s 1, 2 ili 3 supstituenata, te je svaki supstituent neovisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila; Het je monociklički heterocikal odabran od N-fenoksipiperidinila, piperidinila, pirolila, pirazolila, imidazolila, furanila, tienila, oksazolila, izoksazolila, tiazolila, izotiazolila, piridinila, pirimidinila, pirazinila ili piridazinila; ili biciklički heterocikal odabran od kinolinila, kinoksalinila, indolila, benzimidazolila, benzoksazolila, benzizoksazolila, benzotiazolila, benzizotiazolila, benzofuranila, benzotienila, 2,3-dihidrobenzo[1,4]dioksinila ili benzo[1,3]dioksolila; svaki monociklički i biciklički heterocikal je proizvoljno supstituiran s 1, 2 ili 3 supstituenata, te je svaki supstituent neovisno odabran od halo, hidroksi, alkila ili alkiloksi; halo je supstituent odabran od fluoro, kloro, bromo ili jodo; i haloalkil je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma vezanih na ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; pri čemu su jedan ili više ugljikovih atoma supstituirani s jednim ili više halo atoma.
2. Spoj prema zahtjevu 1, naznačen time da p je 0 ili 1; R1 je halo ili alkil; R2 je alkiloksi ili aril; R3 je aril, arilalkil ili Het-alkil; q je 1; R4 i R5 svaki neovisno su alkil ili R4 i R5zajedno s dušikovim atomom na koji su vezani tvore 4-tiomorfolino, piperidino ili piperazino radikal supstituiran s alkilom ili arilalkilom; R6 je aril proizvoljno supstituiran sa halo, ili R6 je benzofuranil; R7 je vodik; i R8 je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 4 ugljikovih atoma.
3. Spoj prema bilo kojem od zahtjeva 1 i 2, naznačen time da p je 1; Z je radikal s formulom (a); R1 je bromo ili metil; R2 je metiloksi ili fenil; R3 je fenil proizvoljno supstituiran s metiloksi, ili benzilom; q je 1; R4 i R5 su svaki metil, etil ili izopropil, ili R4 i R5 zajedno s dušikovim atomom na koji su vezani tvore 4-tiomorfolino radikal, piperidino radikal supstituiran s metilom na 4-položaju ili piperazino radikal supstituiran s benzilom na 4-položaju; R6 je fenil ili benzofuranil; i R7 je vodik.
4. Spoj prema zahtjevu 2, naznačen time da p je 0 ili l; R1 je bromo ili metil; R2 je metiloksi ili fenil; R3 je fenil, benzil ili kinolin-5-ilmetil; q je 1; R4 i R5 su svaki metil ili R4 i R5zajedno s dušikovim atomom na koji su vezani tvore piperazino radikal supstituiran s metilom na 4-položaju; R6 je fenil proizvoljno supstituiran s fluoro na 2-položaju; R7 je vodik; i R8 je etil.
5. Spoj naznačen time da je odabran iz skupa koji čine: 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-N-(4-metil-piperazin-1-il)-acetamid; N-[(6-bromo-2-metoksi-kinolin-3-il)-fenil-metil]-N',N'-dimetil-N-feniletan-1,2-diamin; N-benzil-N-[(6-bromo-2-fenil-kinolin-3-il)-fenil-metil]-N',N'-dimetiletan-1,2-diamin; 2- {benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-1-(4-metil-piperazin-1-il)-etanon; 2-{[(6-bromo-2-metoksi-kinolin-3-il)-fenil-metil]-kinolin-5-ilmetilamino}-1-(4-metil-piperazin-1-il)-etanon; 2-{benzil-[(6-bromo-2-metoksi-kinolin-3-il)-fenil-metil]-amino}-1-(4-metil-piperazin-1-il)-etanon; N-benzil-N-[(6-bromo-2-metoksi-kinolin-3-il)-(2-fluoro-fenil)-metil]-N',N'-dimetil-etan-1,2-diamin; etil ester {benzil-[(6-bromo-2-metoksi-kinolin-3-il)-fenil-metil]-amino}-octene kiseline; i 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-1-piperidino-1-il-etanon; njihova farmaceutski prihvatljiva kisela ili bazična adicijska sol, njihov kvarterni amin, njihov stereokemijski izomerni oblik, njihov tautomerni oblik ili njihov N-oksidni oblik.
6. Spoj naznačen time da je odabran iz skupa koji čine: 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-1-(4-benzil-piperazin-1-il)-etanon; N-[(6-bromo-2-metoksi-kinolin-3-il)-fenil-metil]-N-(2-metoksi-fenil)-N',N'-dimetil-etan-1,2-diamin; 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-N,N-dimetil-acetamid; N-benzil-N-[(6-bromo-2-fenil-kinolin-3-il)-fenil-metil]-N',N'-dimetiletan-1,2-diamin; 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-1-(4-metil-piperidin-1-il)-etanon; 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-N,N-dietil-acetamid; 2-{benzil-[(6-bromo-2-fenil-kinolin-3-il)-fenil-metil]-amino}-N,N-dimetil-acetamid; 2-{[benzofuran-2-il-(2-fenil-kinolin-3-il)-metil]-benzil-amino}-N-izopropil-N-metil-acetamid; 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-1-tiomorfolin-4-il-etanon; i 2-{benzil-[(6-metil-2-fenil-kinolin-3-il)-fenil-metil]-amino}-N-izopropil-N-metil-acetamid; njihova farmaceutski prihvatljiva kisela ili bazična adicijska sol, njihov kvarterni amin, njihov stereokemijski izomerni oblik, njihov tautomerni oblik ili njihov N-oksidni oblik.
7. Spoj prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu kao lijek.
8. Pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak, terapijski učinkovitu količinu spoja kako je definirano u bilo kojem od zahtjeva 1 do 6.
9. Uporaba spoja prema bilo kojem od zahtjeva 1 do 6 ili pripravka prema zahtjevu 8 naznačena time da je za proizvodnju lijeka za liječenje bakterijske bolesti.
10. Spoj prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu za liječenje bakterijske bolesti.
11. Kombinacija (a) spoja prema bilo kojem od zahtjeva 1 do 6, te (b) jednog ili više drugih antibakterijskih sredstava, naznačena time da je za uporabu kao lijek.
HRP20151308TT 2005-07-28 2015-12-01 Antibakterijski derivati kinolina HRP20151308T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106962 2005-07-28
EP06777972.8A EP1912948B1 (en) 2005-07-28 2006-07-26 Antibacterial quinoline derivatives
PCT/EP2006/064656 WO2007014885A1 (en) 2005-07-28 2006-07-26 Antibacterial quinoline derivatives

Publications (1)

Publication Number Publication Date
HRP20151308T1 true HRP20151308T1 (hr) 2016-01-01

Family

ID=35610159

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151308TT HRP20151308T1 (hr) 2005-07-28 2015-12-01 Antibakterijski derivati kinolina

Country Status (31)

Country Link
US (1) US7915292B2 (hr)
EP (1) EP1912948B1 (hr)
JP (1) JP5100647B2 (hr)
KR (1) KR101334719B1 (hr)
CN (1) CN101273016B (hr)
AP (1) AP2322A (hr)
AR (1) AR054587A1 (hr)
AU (1) AU2006274918B2 (hr)
BR (1) BRPI0614122B8 (hr)
CA (1) CA2614981C (hr)
CY (1) CY1117247T1 (hr)
DK (1) DK1912948T3 (hr)
EA (1) EA015617B1 (hr)
ES (1) ES2554924T3 (hr)
HK (1) HK1122804A1 (hr)
HR (1) HRP20151308T1 (hr)
HU (1) HUE026259T2 (hr)
IL (1) IL188987A0 (hr)
JO (1) JO3077B1 (hr)
MX (1) MX2008001219A (hr)
MY (1) MY148219A (hr)
NO (1) NO341795B1 (hr)
NZ (1) NZ565946A (hr)
PL (1) PL1912948T3 (hr)
PT (1) PT1912948E (hr)
RS (1) RS54382B1 (hr)
SI (1) SI1912948T1 (hr)
TW (1) TWI427065B (hr)
UA (1) UA94051C2 (hr)
WO (1) WO2007014885A1 (hr)
ZA (1) ZA200800783B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
US20130065922A1 (en) * 2010-05-21 2013-03-14 Syngenta Crop Protection Llc Novel amides as fungicides
AU2013254674B2 (en) 2012-04-27 2017-02-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
PL2841426T3 (pl) 2012-04-27 2017-03-31 Janssen Pharmaceutica N.V. Przeciwbakteryjne pochodne chinoliny
ES2596243T3 (es) * 2012-08-24 2017-01-05 F. Hoffmann-La Roche Ag Nuevos derivados bicíclicos de piridina
CN104650054B (zh) * 2013-11-25 2019-09-13 重庆医药工业研究院有限责任公司 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
US20190321324A1 (en) * 2016-12-30 2019-10-24 Board Of Regents, The University Of Texas System Quaternary amine antibiotic therapeutics
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1041035A3 (ru) * 1982-02-25 1983-09-07 Киорин Сейяку Кабусики Кайся (Фирма) Способ получени производных хинолинкарбоновой кислоты,их гидратов или солей
JPS6463518A (en) * 1987-09-02 1989-03-09 Otsuka Pharma Co Ltd Antiarrhythmic agent
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
DE69518075T2 (de) * 1994-05-24 2001-03-22 Hoffmann La Roche Tricyclische dicarbonylderivate
CA2330564A1 (en) * 1998-04-29 1999-11-04 John Stephen Elder Quinolones used as mrs inhibitors and bactericides
SI2301544T1 (sl) * 2002-07-25 2013-01-31 Janssen Pharmaceutica, N.V. Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje

Also Published As

Publication number Publication date
HUE026259T2 (en) 2016-06-28
BRPI0614122B1 (pt) 2020-09-24
UA94051C2 (ru) 2011-04-11
EA015617B1 (ru) 2011-10-31
BRPI0614122A8 (pt) 2019-01-29
TW200800901A (en) 2008-01-01
NO20081008L (no) 2008-02-27
DK1912948T3 (en) 2016-01-18
IL188987A0 (en) 2008-08-07
KR20080031973A (ko) 2008-04-11
RS54382B1 (en) 2016-04-28
PL1912948T3 (pl) 2016-02-29
WO2007014885A1 (en) 2007-02-08
CY1117247T1 (el) 2017-04-05
AU2006274918A1 (en) 2007-02-08
MX2008001219A (es) 2008-03-24
CN101273016B (zh) 2013-01-02
NZ565946A (en) 2010-11-26
CA2614981C (en) 2014-06-03
HK1122804A1 (en) 2009-05-29
CN101273016A (zh) 2008-09-24
ES2554924T3 (es) 2015-12-28
AP2322A (en) 2011-11-18
US20080182855A1 (en) 2008-07-31
EP1912948A1 (en) 2008-04-23
BRPI0614122A2 (pt) 2011-03-09
JP2009502869A (ja) 2009-01-29
JO3077B1 (ar) 2017-03-15
TWI427065B (zh) 2014-02-21
AU2006274918B2 (en) 2011-09-22
CA2614981A1 (en) 2007-02-08
EA200800455A1 (ru) 2008-10-30
AR054587A1 (es) 2007-06-27
ZA200800783B (en) 2009-06-24
JP5100647B2 (ja) 2012-12-19
SI1912948T1 (sl) 2016-01-29
PT1912948E (pt) 2015-12-21
NO341795B1 (no) 2018-01-22
BRPI0614122B8 (pt) 2023-01-10
KR101334719B1 (ko) 2013-11-29
EP1912948B1 (en) 2015-09-09
US7915292B2 (en) 2011-03-29
MY148219A (en) 2013-03-29

Similar Documents

Publication Publication Date Title
HRP20151308T1 (hr) Antibakterijski derivati kinolina
HRP20110392T1 (hr) Derivati kinolina za liječenje latentne tuberkuloze
RS54794B1 (sr) Antibakterijski derivati hinolina
HRP20131116T1 (hr) Derivati kinolina kao antibakterijska sredstva
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
HRP20171028T1 (hr) Indolski i indazolski spojevi koji aktiviraju ampk
JP2009502869A5 (hr)
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
RS53191B (en) HINOLINE DERIVATIVES AS ANTI-BACTERIAL AGENTS
HRP20160118T1 (hr) HETEROCIKLIÄŚKI DERIVAT KAO INHIBITOR MIKROSOMSKIH SINTAZA PROSTAGLANDINA E (mPGEs)
JP2012224649A5 (hr)
CA2478229A1 (en) Pyridinoylpiperidines as 5-ht1f agonists
RU2007100136A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
HRP20090673T1 (hr) Derivati kvinolina i njihova uporaba kao mikobakterijskih inhibitora
CA2554049A1 (en) Quinoline derivatives for use as mycobacterial inhibitors
CN101584691A (zh) 影响葡糖激酶的化合物
HRP20120510T1 (hr) Derivati beta amino kiseline za liječenje dijabetesa
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
JP2016507502A5 (hr)
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
HRP20120919T1 (hr) 2-[4-(pirazol-4-ilalkil)piperazin-1-il]-3-fenilpirazini i -piridini i 3-[4-(pirazol-4-ilalkil)piperazin-1-il]-2-fenilpiridini kao antagonisti receptora 5-ht7
AR064153A1 (es) Derivados de quinolina antibacterianos. procesos de obtencion y composiciones farmaceuticas.
HRP20161286T1 (hr) Novi anti-invazivni spojevi
HRP20140588T1 (hr) Spojevi kondenziranog prstena i njihova uporaba